Correspondence 0001104659-24-105457 from Camp4 Therapeutics Corp (CAMP) (CIK 0001736730) (CAMP)
Camp4 Therapeutics Corp (CAMP) (CIK 0001736730)
Date: Oct. 2, 2024 · CIK: 0001736730 · Accession: 0001104659-24-105457
AI Filing Summary & Sentiment
File numbers found in text: 333-282241
Letter
ROPES & GRAY LLP
PRUDENTIAL TOWER
800 BOYLSTON STREET
BOSTON, MA 02199-3600
WWW.ROPESGRAY.COM
October 2, 2024
VIA EDGAR AND SECURE FILE TRANSFER
U.S. Securities and Exchange Commission
Division of Corporation Finance, Office of Life Sciences
100 F Street, N.E. Washington, D.C. 20549
Attention: Lauren Sprague Hammill
Re: CAMP4 Therapeutics Corporation
Amendment No. 1 to Registration Statement on Form S-1
Filed September 26, 2024
File No. 333-282241
Ladies and Gentlemen:
On behalf of CAMP4 Therapeutics Corporation (the “Company”), we hereby submit to the U.S. Securities and Exchange Commission (the “Commission”), via EDGAR, the following response to the comment letter from the staff of the Division of Corporation Finance (the “Staff”) of the Commission, dated October 2, 2024, regarding Amendment No. 1 (“Amendment No. 1”) to the above-referenced registration statement (the “Registration Statement”).
To assist your review, we have presented the text of the Staff’s comment in italics below. The response and information described below are based upon information provided to us by the Company and all terms used but not defined herein have the meanings assigned to such terms in Amendment No. 1.
Amendment No. 1 to Registration Statement on Form S-1
Prospectus Summary, CMP-CPS-001: Potential treatment for urea cycle disorders, page 5
1. We note your disclosure on pages 5 and 130 that as of September 2024, the Safety Review Committee of your Phase 1 clinical trial of CMP-CPS-001 has reviewed all reported interim safety data, including treatment emergent adverse events from SAD cohorts 1 through 3, and that to date, "no safety trends of concern have been observed, and CMP-CPS-001 has been well tolerated." Please tell us whether any treatment related serious adverse events ("SAEs") occurred in your clinical trial, and if so, describe each SAE and quantify the number of occurrences. Alternatively, if true, affirmatively state that no SAEs occurred.
- 2 - VIA EDGAR AND SECURE FILE TRANSFER
Response to Comment 1:
The Company acknowledges the Staff’s comment and respectfully confirms to the Staff that no treatment-related serious adverse events have been observed to date in the Company’s ongoing Phase 1 clinical trial of CMP-CPS-001. The Company undertakes to include an affirmative statement to this effect in a subsequent amendment to the Registration Statement.
******
Please do not hesitate to call me at (617) 235-4961 or Lisa Folkerth at (617) 951-7791 with any questions or further comments you may have regarding this filing or if you wish to discuss the above response.
Sincerely,
/s/ Thomas J. Danielski
Show Raw Text
CORRESP
1
filename1.htm
ROPES & GRAY LLP
PRUDENTIAL TOWER
800 BOYLSTON STREET
BOSTON, MA 02199-3600
WWW.ROPESGRAY.COM
October 2, 2024
VIA EDGAR AND SECURE FILE TRANSFER
U.S. Securities and Exchange Commission
Division of Corporation Finance, Office of Life Sciences
100 F Street, N.E. Washington, D.C. 20549
Attention: Lauren Sprague Hammill
Re: CAMP4 Therapeutics Corporation
Amendment No. 1 to Registration Statement
on Form S-1
Filed September 26, 2024
File No. 333-282241
Ladies and Gentlemen:
On behalf of CAMP4 Therapeutics Corporation (the
“Company”), we hereby submit to the U.S. Securities and Exchange Commission (the “Commission”),
via EDGAR, the following response to the comment letter from the staff of the Division of Corporation Finance (the “Staff”)
of the Commission, dated October 2, 2024, regarding Amendment No. 1 (“Amendment No. 1”) to the above-referenced
registration statement (the “Registration Statement”).
To assist your review, we have presented the text
of the Staff’s comment in italics below. The response and information described below are based upon information provided to us
by the Company and all terms used but not defined herein have the meanings assigned to such terms in Amendment No. 1.
Amendment No. 1 to Registration Statement on Form S-1
Prospectus Summary, CMP-CPS-001: Potential treatment for urea
cycle disorders, page 5
1. We
note your disclosure on pages 5 and 130 that as of September 2024, the Safety Review Committee of your Phase 1 clinical trial
of CMP-CPS-001 has reviewed all reported interim safety data, including treatment emergent adverse events from SAD cohorts 1 through 3,
and that to date, "no safety trends of concern have been observed, and CMP-CPS-001 has been well tolerated." Please tell us
whether any treatment related serious adverse events ("SAEs") occurred in your clinical trial, and if so, describe each SAE
and quantify the number of occurrences. Alternatively, if true, affirmatively state that no SAEs occurred.
- 2 - VIA
EDGAR AND SECURE FILE TRANSFER
Response to Comment 1:
The Company acknowledges the Staff’s comment
and respectfully confirms to the Staff that no treatment-related serious adverse events have been observed to date in the Company’s
ongoing Phase 1 clinical trial of CMP-CPS-001. The Company undertakes to include an affirmative statement to this effect in a subsequent
amendment to the Registration Statement.
******
Please do not hesitate to call me at (617) 235-4961
or Lisa Folkerth at (617) 951-7791 with any questions or further comments you may have regarding this filing or if you wish to discuss
the above response.
Sincerely,
/s/ Thomas J. Danielski
Thomas J. Danielski
cc. Josh Mandel-Brehm (CAMP4 Therapeutics Corporation)
cc. Kelly
Gold (CAMP4 Therapeutics Corporation)
cc. Lisa Folkerth (Ropes & Gray LLP)
cc. Seo Salimi (Paul Hastings LLP)
cc. Will Magioncalda (Paul Hastings LLP)